| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 01/17/2002 | WO2002004618A1 Methods of producing and using a human microglial cell line |
| 01/17/2002 | WO2002004606A1 Use of bioactive glass compositions to stimulate osteoblast production |
| 01/17/2002 | WO2002004604A2 Immortalized human microglia cell and continuous cell line |
| 01/17/2002 | WO2002004596A2 Diagnosing and treating cancer cells using mutant viruses |
| 01/17/2002 | WO2002004522A2 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 01/17/2002 | WO2002004511A2 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
| 01/17/2002 | WO2002004493A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/17/2002 | WO2002004487A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 01/17/2002 | WO2002004479A1 TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD |
| 01/17/2002 | WO2002004037A1 Biomaterial including animal corneal tissue |
| 01/17/2002 | WO2002004019A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 01/17/2002 | WO2002004014A1 New class of bioactive glycoprotein |
| 01/17/2002 | WO2002004010A2 Inhibition of tumor growth by a nematode anticoagulant protein |
| 01/17/2002 | WO2002004006A2 Method for improving the efficacy of artificial insemination of non-human animals |
| 01/17/2002 | WO2002004002A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 01/17/2002 | WO2002004001A2 A composition for the delivery of live cells and methods of use |
| 01/17/2002 | WO2002003910A2 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001041775A3 Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response |
| 01/17/2002 | WO2001040455A3 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals |
| 01/17/2002 | WO2001037847A3 Nontoxic vernix compositions and method of producing |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001029192A3 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 01/17/2002 | WO2001027623A3 Isoagglutinin-depleted blood compositions and methods of making same |
| 01/17/2002 | WO2001027290A3 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001016293A3 Dna encoding the human serine protease t |
| 01/17/2002 | WO2001015710A3 A method of treatment of human immunodeficiency diseases |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | US20020007223 Method of organogenesis and tissue regeneration/repair using surgical techniques |
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006663 p27 and p21 in gene therapies |
| 01/17/2002 | US20020006660 Genetically-modified neural progenitors and uses thereof |
| 01/17/2002 | US20020006649 Matrix; for use in wound healing |
| 01/17/2002 | US20020006630 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| 01/17/2002 | US20020006450 Improved physical properties and shelf life, in the form of powdered clathrates in which Aureobacidium culture solution as a guest is included in cyclodextrin as a host component |
| 01/17/2002 | US20020006448 Compositions and methods for treating back and leg discomfort |
| 01/17/2002 | US20020006444 Extract from a plant crude drug, having given amount of soluble silicon compound calculated as silicon per gram of dry weight, and extract that inhibits production of plasma kallikrein; standardization |
| 01/17/2002 | US20020006432 Bifidobacterium in the treatment of inflammatory disease |
| 01/17/2002 | US20020006398 Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions |
| 01/17/2002 | US20020006392 Isolating peripheral mononuclear blood cells from a recipient and a donor; mixing donor and recipient cells ex vivo, treating the cells with a regulatory composition (TGF-beta) transforming growth factor to activate the cells |
| 01/17/2002 | US20020006383 Promoter of biosynthesis of skin cells |
| 01/17/2002 | US20020005205 Joint repair using mesenchymal stem cells |
| 01/17/2002 | CA2427066A1 Method for the recovery and application of human defensins as biologically active proteins for the treatment of infections and other diseases |
| 01/17/2002 | CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use |
| 01/17/2002 | CA2415422A1 Chromosome 3p21.3 genes are tumor suppressors |
| 01/17/2002 | CA2414510A1 Use of bioactive glass compositions to stimulate osteoblast production |
| 01/17/2002 | CA2414374A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/17/2002 | CA2414272A1 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 01/17/2002 | CA2412581A1 Transforming growth factor beta (tgf-.beta.) blocking agent-treated stem cell composition and method |
| 01/17/2002 | CA2385142A1 New class of bioactive glycoprotein |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171624A1 Method and means for producing high titer, safe, recombinant lentivirus vectors |
| 01/16/2002 | EP1171616A1 Method for enhancing myoblast migration and invasion in the context of gene therapy |
| 01/16/2002 | EP1171608A2 Recombinant and mutant marek's disease virus |
| 01/16/2002 | EP1171600A2 Zalpha13: a human secreted protein |
| 01/16/2002 | EP1171586A2 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/16/2002 | EP1171578A2 Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof |
| 01/16/2002 | EP1171577A2 Anti-bacterial vaccine compositions |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171469A1 ANTI-p53 ANTIBODIES |
| 01/16/2002 | EP1171454A1 Chimeric lyssavirus nucleic acids and polypeptides |
| 01/16/2002 | EP1171219A1 Biological fluid filter and system |
| 01/16/2002 | EP1171165A1 Intramyocardial injection of autologous bone marrow |
| 01/16/2002 | EP1171163A1 Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| 01/16/2002 | EP1171156A1 Novel use within transplantation surgery |
| 01/16/2002 | EP1171153A2 Novel medical use of alpha-1-acidic glycoprotein (aag) or orosomucoid |
| 01/16/2002 | EP1171140A2 Treatment of hypersensitivity reaction disorders |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP1171057A1 Cell-culture and polymer constructs |
| 01/16/2002 | EP1093374B1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/16/2002 | EP0787007B1 Anti-inflammatory factor, method of isolation, and use |
| 01/16/2002 | EP0722344B1 Process for virus deactivation in the presence of a polyether and an agens |
| 01/16/2002 | EP0697875B1 Use of modified tall-104 cells to treat cancer and viral diseases |
| 01/16/2002 | CN1331699A Methods of identifying antigen gene sequences |
| 01/16/2002 | CN1331587A Spray-type consmetic compsn. and matrix used in said compsn. for dermal administration |
| 01/16/2002 | CN1330955A Instant particles for regulating growth and trace element absorption of human bone |
| 01/16/2002 | CN1330953A Exterior-applied Chinese medicine 'Zhizaoling' for preventing and treating ejaculation praecox and its preparing process and application |
| 01/16/2002 | CN1330951A Chinese medicine for treating dermatopathy (leukoderma and psoriasis) |
| 01/16/2002 | CN1330950A Chinese medicine for optimally taking care of brain health |
| 01/16/2002 | CN1330935A Drug-dropping Chinese patent medicine for improving immunity of human body itself |
| 01/16/2002 | CN1330933A Chinese medicine for treating hepatism |
| 01/16/2002 | CN1330930A Medicine for treating cardiovascular disease |
| 01/16/2002 | CN1330925A Instant bee pollen and its preparing process |
| 01/16/2002 | CN1330924A Process for refining Chinese medicines by adsorption of composite spherical activated carbon |
| 01/16/2002 | CN1077797C Chinese medicine powder for curing leukemia |
| 01/16/2002 | CN1077793C Chinese drug compsn. for curing periodontitis |
| 01/15/2002 | US6339149 Isolated nucleic acid molecules which encode tumor rejection antigens found in dage |
| 01/15/2002 | US6339139 Receptor-mediated gene transfer system for targeting tumor gene therapy |
| 01/15/2002 | US6339106 Methods and compositions for the treatment and prevention of sexual dysfunction |
| 01/15/2002 | US6339070 Gene directed enzyme prodrug therapy (gdept) using in situ antibody generation to provide enhanced selectivity, in cancer therapy; for delivering cytotoxic drugs |
| 01/15/2002 | US6339065 Episomal expression vector for human gene therapy |
| 01/15/2002 | US6338953 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |
| 01/15/2002 | US6338845 Tumor killing effects of enterotoxins, superantigens, and related compounds |
| 01/15/2002 | CA2030951C Process for producing immunostimulant agents |
| 01/10/2002 | WO2002002765A2 Chimeric promoters for controlling expression in smooth muscle cells |
| 01/10/2002 | WO2002002751A2 Alteration of cell membrane |